Melody Cobleigh to Biomarkers, Tumor
This is a "connection" page, showing publications Melody Cobleigh has written about Biomarkers, Tumor.
Connection Strength
1.179
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Score: 0.603
-
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31.
Score: 0.229
-
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
Score: 0.146
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
Score: 0.082
-
Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002 Nov-Dec; 8(6):349-55.
Score: 0.046
-
Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Res Treat. 2017 Nov; 166(1):315-319.
Score: 0.032
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
Score: 0.017
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
Score: 0.013
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.010